Plaza-Menacho I - Search Results

1

RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements.

Plaza-Menacho I, Barnouin K, Barry R, Borg A, Orme M, Chauhan R, Mouilleron S, Martínez-Torres RJ, Meier P, McDonald NQ. Plaza-Menacho I, et al. Cell Rep. 2016 Dec 20;17(12):3319-3332. doi: 10.1016/j.celrep.2016.11.061. Cell Rep. 2016. PMID: 28009299 Free PMC article.

2

Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.

Plaza-Menacho I, Barnouin K, Goodman K, Martínez-Torres RJ, Borg A, Murray-Rust J, Mouilleron S, Knowles P, McDonald NQ. Plaza-Menacho I, et al. Mol Cell. 2014 Mar 6;53(5):738-51. doi: 10.1016/j.molcel.2014.01.015. Epub 2014 Feb 20. Mol Cell. 2014. PMID: 24560924 Free PMC article.

3

Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.

Plaza-Menacho I, Mologni L, McDonald NQ. Plaza-Menacho I, et al. Cell Signal. 2014 Aug;26(8):1743-52. doi: 10.1016/j.cellsig.2014.03.032. Epub 2014 Apr 3. Cell Signal. 2014. PMID: 24705026 Review.

4

Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.

Plaza-Menacho I, Morandi A, Mologni L, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RM, Knowles P, McDonald NQ, Isacke CM. Plaza-Menacho I, et al. J Biol Chem. 2011 May 13;286(19):17292-302. doi: 10.1074/jbc.M110.168500. Epub 2011 Mar 22. J Biol Chem. 2011. PMID: 21454698 Free PMC article.

5

RET in breast cancer: functional and therapeutic implications.

Morandi A, Plaza-Menacho I, Isacke CM. Morandi A, et al. Trends Mol Med. 2011 Mar;17(3):149-57. doi: 10.1016/j.molmed.2010.12.007. Epub 2011 Jan 19. Trends Mol Med. 2011. PMID: 21251878 Review.

6

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.

Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM. Plaza-Menacho I, et al. Oncogene. 2010 Aug 19;29(33):4648-57. doi: 10.1038/onc.2010.209. Epub 2010 Jun 7. Oncogene. 2010. PMID: 20531297

7

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM. Plaza-Menacho I, et al. J Biol Chem. 2007 Oct 5;282(40):29230-40. doi: 10.1074/jbc.M703461200. Epub 2007 Jul 30. J Biol Chem. 2007. PMID: 17664273 Free article.

8

Structure and function of RET in multiple endocrine neoplasia type 2.

Plaza-Menacho I. Plaza-Menacho I. Endocr Relat Cancer. 2018 Feb;25(2):T79-T90. doi: 10.1530/ERC-17-0354. Epub 2017 Nov 24. Endocr Relat Cancer. 2018. PMID: 29175871 Review.

9

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM. Morandi A, et al. Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6. Cancer Res. 2013. PMID: 23650283 Free PMC article.

10

Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability.

Shehata MA, Contreras J, Martín-Hurtado A, Froux A, Mohamed HT, El-Sherif AA, Plaza-Menacho I. Shehata MA, et al. Among authors: plaza menacho i. J Adv Res. 2023 Mar;45:87-100. doi: 10.1016/j.jare.2022.05.004. Epub 2022 May 17. J Adv Res. 2023. PMID: 35595215 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters